Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of some unusual options trading on Wednesday. Stock traders bought 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock opened at $3.68 on Friday. The stock’s fifty day simple moving average is $3.28 and its 200 day simple moving average is $3.38. The company has a current ratio of 6.60, a quick ratio of 5.69 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $946.02 million, a PE ratio of -4.09 and a beta of 0.43. Maravai LifeSciences has a 12 month low of $1.95 and a 12 month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%.The company had revenue of $49.87 million during the quarter, compared to the consensus estimate of $49.06 million. On average, research analysts predict that Maravai LifeSciences will post -0.26 EPS for the current year.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in MRVI. T. Rowe Price Investment Management Inc. increased its holdings in Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock worth $20,595,000 after purchasing an additional 178,445 shares in the last quarter. Mackenzie Financial Corp grew its stake in shares of Maravai LifeSciences by 1.7% during the 4th quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after acquiring an additional 104,355 shares in the last quarter. Monaco Asset Management SAM grew its stake in shares of Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter. Tejara Capital Ltd raised its holdings in shares of Maravai LifeSciences by 23.1% in the fourth quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock valued at $9,816,000 after purchasing an additional 566,768 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Maravai LifeSciences by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock worth $9,259,000 after purchasing an additional 34,447 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.